💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Britain says talking to Pfizer, AstraZeneca, but deal is for shareholders

Published 06/05/2014, 12:59
Updated 06/05/2014, 13:32
AZN
-
PFE
-

LONDON (Reuters) - Britain will continue to speak with U.S. drugmaker Pfizer (N:PFE) and British pharmaceutical firm AstraZeneca (L:AZN) about any potential takeover but any deal is a commercial decision, Prime Minister David Cameron's spokesman said.

When asked about the potential takeover by reporters, Cameron's spokesman said: "We will engage very actively with both companies in terms of the importance of R&D, of skills, of expanding the skill base in the UK and we will keep doing that."

The spokesman said a decision any deal was "a commercial decision between shareholders" and that the British government was "very clear that is for the shareholders and no one else."

(Reporting by William James, writing by Guy Faulconbridge, editing by Michael Holden)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.